Merck

Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.

Biological & pharmaceutical bulletin (2014-11-05)
Yoshihiko Shimokawa, Katsunori Sasahara, Noriaki Yoda, Katsuhiko Mizuno, Ken Umehara
ABSTRACT

Delamanid is a new drug for the treatment of multidrug-resistant tuberculosis. Individuals who are co-infected with human immunodeficiency virus and Mycobacterium tuberculosis may require treatment with a number of medications that might interact significantly with the CYP enzyme system as inhibitors or inducers. It is therefore important to understand how drugs in development for the treatment of tuberculosis will affect CYP enzyme metabolism. The ability of delamanid to inhibit or induce CYP enzymes was investigated in vitro using human liver microsomes or human hepatocytes. Delamanid (100 µM) had little potential for mechanism-based inactivation on eight CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). Delamanid's metabolites were noted to inhibit the metabolism of some CYP isoforms, but these effects were observed only at metabolite concentrations that were well above those observed in human plasma during clinical trials. Delamanid (≤10 µM) did not induce CYP1A2, CYP2C9, and CYP3A4 activities in human hepatocytes, and there were no increases in CYP1A2, CYP2B6, CYP2C9, and CYP3A4 mRNA levels. Taken together, these data suggest that delamanid is unlikely to cause clinically relevant drug-drug interactions when co-administered with products that are metabolized by the CYP enzyme system.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acetaminophen, analytical standard
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
Umbelliferone, 99%
Supelco
Tolbutamide, analytical standard
Sigma-Aldrich
Umbelliferone, suitable for fluorescence indicator, ≥98.0% (HPLC)
Sigma-Aldrich
Chlorzoxazone
Diclofenac sodium, European Pharmacopoeia (EP) Reference Standard
Supelco
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Umbelliferone, analytical standard
USP
Diclofenac sodium, United States Pharmacopeia (USP) Reference Standard
Nifedipine impurity A, European Pharmacopoeia (EP) Reference Standard
Tolbutamide, European Pharmacopoeia (EP) Reference Standard
USP
Acetaminophen, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Diclofenac sodium salt
USP
Nifedipine Nitrophenylpyridine Analog, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Hypoxanthine, ≥99.0%
Sigma-Aldrich
Nifedipine, ≥98% (HPLC), powder
Sigma-Aldrich
Hypoxanthine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Phenacetin, ≥98.0% (HPLC)
Supelco
Testosterone, VETRANAL®, analytical standard
Sigma-Aldrich
Testosterone, purum, ≥99.0% (HPLC)
Sigma-Aldrich
6-Hydroxychlorzoxazone, ≥98% (HPLC)
Sigma-Aldrich
Oxidized Nifedipine, powder, ~95% (HPLC)
Testosterone, European Pharmacopoeia (EP) Reference Standard
Supelco
Phenacetin melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Diclofenac sodium salt, analytical standard
Supelco
Diclofenac sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Resorufin, 95%